HIV-associated wasting in the era of highly active antiretroviral therapy: a syndrome of residual HIV infection in monocytes and macrophages?
Human immunodeficiency virus (HIV) infection in peripheral blood mononuclear cells (PBMCs) might be influencing the development of wasting in the era of potent antiretroviral therapy. In a retrospective study of 57 subjects, HIV proviral DNA levels in PBMCs were higher in subjects whose body weight decreased by >5% one year after initiation of highly active antiretroviral therapy, compared with subjects whose body weight was stable or increased (median HIV proviral DNA load, 8.9 vs. 0.9 copies/10(6) PBMCs; P = .006).
Shikuma
Cecilia M
CM
Hawaii AIDS Clinical Research Program, John A. Burns School of Medicine, University of Hawaii-Manoa, Honolulu, Hawaii 96816, USA. shikuma@hawaii.edu
Valcour
Victor G
VG
Ratto-Kim
Silvia
S
Williams
Andrew E
AE
Souza
Scott
S
Gerschenson
Mariana
M
Day
Larry
L
Kim
Jerome H
JH
Shiramizu
Bruce
B
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000627:therapeutic use; D001835:Body Weight; D018791:CD4 Lymphocyte Count; D016022:Case-Control Studies; D004279:DNA, Viral; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000821:virology*; D019247:HIV Wasting Syndrome / Q000209:etiology* / Q000821:virology*; D006801:Humans; D008875:Middle Aged; D009000:Monocytes / Q000821:virology*; D012189:Retrospective Studies; D019562:Viral Load
D000998:Antiviral Agents; D004279:DNA, Viral